 UPPSALA, Sweden, July 16, 2021 PRNewswire -- Orexo AB publ., STO:ORX OTCQX:ORXOY today announces that the company has successfully initiated the pivotal trial OX124-002 for its lead pharmaceutical pipeline asset, OX124. 